Drugs / Mebufotenin
Mebufotenin
also known as
5-methoxy-N,N-dimethyltryptamine · 5-MeO-DMT · GH001 · 5-methoxy-dimethyltryptamine · 5-methoxy-n-dimethyltryptamine · Mebufotenina · Mebufotenine · NSC-88624
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07540494 | Apr → May 2026 overdue | — | GH Research Ireland Limited | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07444788 | Mar 2026 → Mar 2028 expected | — | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 1 | NCT06511947 | Aug 2024 → Feb 2025 overdue | — | GH Research Ireland Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT05698095 | Dec 2022 → Sep 2023 | — | Usona Institute | Completed | No outcome recorded |
| Phase 1 | NCT05753956 | Dec 2022 → Nov 2023 | — | GH Research Ireland Limited | Completed | No outcome recorded |
| Phase 1 | NCT05347849 | Feb 2022 → Jan 2024 | — | Beckley Psytech Limited | Completed | No outcome recorded |
| Phase 1 | NCT05032833 | Sep 2021 → Jul 2022 | — | Beckley Psytech Limited | Completed | No outcome recorded |
| Phase 1 | NCT05163691 | Jun → Oct 2021 | — | GH Research Ireland Limited | Completed | No outcome recorded |
| Phase 1 | NCT04640831 | Mar → Oct 2019 | — | GH Research Ireland Limited | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06812221 | Dec 2024 → Feb 2025 | anxiety, cognitive impairment with or without cerebellar ataxia, mixed anxiety and depressive disorder | Biomind Labs Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT06816667 | Oct 2024 → Feb 2025 | — | Biomind Labs Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04698603 | Nov 2019 → Nov 2021 | major depressive disorder | GH Research Ireland Limited | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06810765 | Sep 2025 → Dec 2026 | cognitive disorder, post-traumatic stress disorder, traumatic brain injury | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 2 | NCT05800860 | May 2023 → Oct 2024 | — | GH Research Ireland Limited | Completed | No outcome recorded |
| Phase 2 | NCT05839509 | Apr 2023 → Nov 2024 | bipolar II disorder | GH Research Ireland Limited | Terminated | No outcome recorded |
| Phase 2 | NCT05804708 | Mar 2023 → Aug 2024 | postpartum depression | GH Research Ireland Limited | Terminated | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mebufotenin | “Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial.” PMID 42247279 ↗ Jun 2026 |
| Known as | 5-MeO-DMT | “AIMS: To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of...” PMID 38616411 ↗ Apr 20245“The substance 5-MeO-DMT, a potent tryptamine, is known for its psychoactive properties but will be administered at a dose that does not induce a full psychedelic experience.” NCT06816667 ↗ “Participants will receive a single sublingual dose of 6 mg of 5-MeO-DMT once a week for four consecutive weeks.” NCT06812221 ↗ |
| Known as | 5-methoxy-dimethyltryptamine | “The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive...” NCT04698603 ↗ |
| Known as | 5-methoxy-N,N-dimethyltryptamine | “AIMS: To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of...” PMID 38616411 ↗ Apr 20247“A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression.” PMID 37409159 ↗ Jun 2023 “5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects.” PMID 34912222 ↗ Nov 2021 |
| Known as | 5-methoxy-n-dimethyltryptamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL7257 ↗ |
| Known as | GH001 | “Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial.” PMID 42247279 ↗ Jun 2026 |
| Known as | Mebufotenina | ChEMBL registry synonym — accepted as the source's own label CHEMBL7257 ↗ |
| Known as | Mebufotenine | ChEMBL registry synonym — accepted as the source's own label CHEMBL7257 ↗ |
| Known as | NSC-88624 | ChEMBL registry synonym — accepted as the source's own label CHEMBL7257 ↗ |
| Action | Activate | “5-MeO-DMT, as described in the study, is a 5-HT 2A agonist compound” NCT06810765 ↗ |
| Modality | Small molecule | — CHEMBL7257 ↗ |
| Route | Intranasal | “administered intranasally” NCT05032833 ↗ |